<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980706</url>
  </required_header>
  <id_info>
    <org_study_id>12-1743</org_study_id>
    <secondary_id>4R01AA020824-04</secondary_id>
    <nct_id>NCT01980706</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of High Dose Baclofen for Alcohol Dependence</brief_title>
  <official_title>Efficacy and Safety of High Dose Baclofen for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will carefully test the hypothesis that a robust dose of baclofen (90
      mg/day) has efficacy and is safe in individuals with alcohol dependence. Furthermore, the
      proposal will test whether an indicator of physical dependence, i.e. drinks/drinking day,
      predicts response to baclofen. Additionally, the proposal will examine the anti-anxiety
      effects of baclofen within an alcohol dependent population and ascertain whether baseline
      levels of anxiety predict response to baclofen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol dependence (AD) is a common problem with significant health consequences. Treatment
      of AD is evolving to include both counseling methods and medications. Several medications
      have been discovered, that show efficacy in AD, e.g. naltrexone, acamprosate. However, the
      overall effect of existing medications is modest leaving a clear need for the development of
      new pharmacotherapies. The gamma-aminobutyric acid (GABA)-B receptor agonist baclofen has
      attracted attention as a potential new medication for AD based on preclinical data and early
      clinical trials. Baclofen is an FDA approved medication with an excellent safety profile even
      for patients with liver cirrhosis—a not uncommon consequence of AD. Questions have arisen
      with regards to the efficacy of baclofen and whether higher doses of baclofen are safe and
      more effective than the prior tested dose of 30 mg/ day. There is emerging evidence that
      severity of dependence is positively associated with baclofen response. The main goal of the
      present proposal is to test the efficacy and safety of 30 mg/d and 90 mg/d of baclofen
      compared to placebo controlling for severity of dependence as assessed by drinks/drinking
      day. A primary secondary goal will examine for an anxiolytic effect of baclofen. The study
      proposes to enroll 120 men and women with AD in a randomized, placebo-controlled trial to
      include at least 60 individuals with more severe AD (≥14 drinks/drinking day for men; ≥10
      drinks/drinking day for women) with randomization to baclofen or placebo balanced for this
      variable. Baclofen will be titrated to 10 mg t.i.d over 3 days and to 30 mg t.i.d over 12
      days and maintained at that level for 12 weeks and then downtitrated for a total study time
      of 16 weeks. Medical Management will be provided to encourage progress towards drinking goals
      and to enhance retention and compliance. Drinking patterns, anxiety levels, sleep patterns,
      craving for alcohol, gamma-glutamyl transferase (GGT) and carbohydrate deficient transferring
      (CDT) will be assessed. Trough blood levels of R &amp; S-baclofen will be assessed in all
      individuals at week 4.

      In summary, the present proposal is innovative and of clinical significance as it will test
      and compare standard and high-dose baclofen for efficacy and safety in individuals with AD.
      The proposal is adequately powered to test the primary hypothesis and provides good power to
      assess whether drinks/drinking day is predictive of baclofen response. Adequate power is also
      present to examine the anxiolytic effect of baclofen. Ascertaining the effects of standard
      and high-dose baclofen, the predictive value of heavy drinking on baclofen response and the
      anxiolytic effect of baclofen are important goals towards determining whether baclofen has
      true value for the clinical management of the patient with alcohol dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2013</start_date>
  <completion_date type="Actual">October 26, 2017</completion_date>
  <primary_completion_date type="Actual">October 26, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage of Heavy Drinking Days</measure>
    <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
    <description>The frequency of heavy drinking days (5 or more drinks for a man and 4 or more drinks for a woman) as percentage during the treatment phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage of Abstinent Drinking Days</measure>
    <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
    <description>Percent of abstinent days over the course of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Spielberger State-Trait Anxiety Inventory Score [State]</measure>
    <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
    <description>The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults.The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety). The scores are averaged over the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Penn Alcohol Craving Scale Score</measure>
    <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
    <description>Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol. Scores are averaged over the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate-deficient Transferrin</measure>
    <time_frame>End of trial, generally 16 weeks</time_frame>
    <description>Lab test assessing history of heavy drinking with greater specificity than GGT. Higher levels are indicative of greater levels of drinking.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Self-reported Sedation on at Least One Occasion by a Participant</measure>
    <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
    <description>Any reporting of feeling sedated/sleepy/drowsy</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 Mg Baclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg Baclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen is a GABA-B agonist</description>
    <arm_group_label>30 Mg Baclofen</arm_group_label>
    <arm_group_label>90 mg Baclofen</arm_group_label>
    <other_name>Lioresal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill containing no pharmacologically active substance.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18 and 65 meeting Diagnostic and Statistical Manual
             (DSM)-IV criteria for current alcohol dependence.

          2. More than 14 drinks (women) or 21 drinks (men) per week including at least 2 heavy
             drinking days (men &gt; 5 drinks/day; women &gt; 4 drinks/day) per week in the 30-day period
             prior to screening. In addition we will recruit 50% of individuals who have a mean of
             ≥14 drinks/drinking day (men) or ≥10 drinks/drinking day (women) in the 30 days prior
             to screening.

          3. Ability to understand and sign written informed consent.

          4. Must have a 0.0 gms/dL breathalyzer reading on the day of screening and 0.0 gms/dL on
             the day of randomization.

          5. Express a desire to achieve abstinence or to greatly reduce alcohol consumption

          6. Must have a stable residence and be able to identify an individual who could contact
             participant if needed.

        Exclusion Criteria:

          1. Clinically significant medical disease that might interfere with the evaluation of the
             study medication or present a safety concern (e.g., renal insufficiency, cirrhosis,
             unstable hypertension, diabetes mellitus, seizure disorder). Clinically significant
             psychiatric illness including any psychotic disorder, bipolar disorder, severe
             depression, or suicidal ideation.

          2. Other substance abuse or dependence disorder other than nicotine or alcohol or
             cannabis abuse.

             Occasional use of cocaine is acceptable.

          3. Concurrent use of any psychotropic medication including antidepressants, mood
             stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception
             of stable doses of antidepressants for one month. Concurrent use of anticonvulsants,
             insulin, or oral hypoglycemics.

          4. Prior history of adverse reaction to baclofen.

          5. Creatinine level &gt; Upper Limit of Normal (ULN) or Estimated Glomerular Filtration Rate
             &lt; age norm.

          6. aspartate aminotransferase (AST), or alanine transaminase (ALT) &gt; 5 times ULN or
             bilirubin &gt; 1.5 X ULN.

          7. Positive urine toxicology screen with the exception of cannabis. Individuals with
             positive cannabis screens will be excluded only if they have a history of cannabis
             dependence.

          8. Pregnant women and women of childbearing potential who do not practice a medically
             acceptable form of birth control (oral or depot contraceptive, or barrier methods such
             as diaphragm or condom with spermicidal).

          9. Women who are breastfeeding.

         10. Individuals requiring inpatient treatment or more intense outpatient treatment for
             their alcohol dependence.

         11. Participation in any clinical trial within the past 60 days.

         12. Court-mandated participation in alcohol treatment or pending incarceration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Garbutt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <results_first_submitted>October 3, 2018</results_first_submitted>
  <results_first_submitted_qc>December 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Baclofen</keyword>
  <keyword>Alcohol Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT01980706/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
        </group>
        <group group_id="P2">
          <title>30 Mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a gamma-aminobutyric acid (GABA)-B receptor agonist</description>
        </group>
        <group group_id="P3">
          <title>90 mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
        </group>
        <group group_id="B2">
          <title>30 Mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
        </group>
        <group group_id="B3">
          <title>90 mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="9.6"/>
                    <measurement group_id="B2" value="46.1" spread="10.4"/>
                    <measurement group_id="B3" value="44.8" spread="10.3"/>
                    <measurement group_id="B4" value="46.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Percentage of Heavy Drinking Days</title>
          <description>Percentage of heavy drinking days over the prior 90 days</description>
          <units>percentage of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" spread="21"/>
                    <measurement group_id="B2" value="73" spread="23"/>
                    <measurement group_id="B3" value="70" spread="26"/>
                    <measurement group_id="B4" value="74" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Percentage of Abstinent Days</title>
          <description>Percentage of abstinent days over the prior 90 days.</description>
          <units>Percentage of Abstinent Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" spread="17"/>
                    <measurement group_id="B2" value="17" spread="19"/>
                    <measurement group_id="B3" value="18" spread="20"/>
                    <measurement group_id="B4" value="16" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Drinks/drinking day</title>
          <units>drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="3.9"/>
                    <measurement group_id="B2" value="10.7" spread="7.7"/>
                    <measurement group_id="B3" value="10.0" spread="4.2"/>
                    <measurement group_id="B4" value="10.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Goal of Abstinence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Craving for Alcohol</title>
          <description>Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="6.8"/>
                    <measurement group_id="B2" value="15.5" spread="7.2"/>
                    <measurement group_id="B3" value="15.3" spread="6.1"/>
                    <measurement group_id="B4" value="15.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbohydrate Deficient Transferrin (CDT)</title>
          <description>laboratory measure that assesses levels of heavy drinking over time with greater specificity than gamma-glutamyl transferase (GGT).</description>
          <population>Not all subjects had CDT analyzed.</population>
          <units>% CDT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.31" spread="1.95"/>
                    <measurement group_id="B2" value="1.72" spread="0.63"/>
                    <measurement group_id="B3" value="2.22" spread="1.46"/>
                    <measurement group_id="B4" value="2.07" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Speilberger State Anxiety</title>
          <description>The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults. The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="10.5"/>
                    <measurement group_id="B2" value="36.3" spread="12.4"/>
                    <measurement group_id="B3" value="35.7" spread="9.7"/>
                    <measurement group_id="B4" value="35.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Heavy Drinking Days</title>
        <description>The frequency of heavy drinking days (5 or more drinks for a man and 4 or more drinks for a woman) as percentage during the treatment phase.</description>
        <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
        <population>Post-randomization data were unavailable for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Heavy Drinking Days</title>
          <description>The frequency of heavy drinking days (5 or more drinks for a man and 4 or more drinks for a woman) as percentage during the treatment phase.</description>
          <population>Post-randomization data were unavailable for 2 participants.</population>
          <units>percentage of heavy drinking days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="4"/>
                    <measurement group_id="O2" value="42" spread="4"/>
                    <measurement group_id="O3" value="28" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.16</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Overall, treatment effect F value testing under the null hypothesis the equality of the average outcome over the three groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Abstinent Drinking Days</title>
        <description>Percent of abstinent days over the course of the trial.</description>
        <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
        <population>Post-randomization data were unavailable for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Abstinent Drinking Days</title>
          <description>Percent of abstinent days over the course of the trial.</description>
          <population>Post-randomization data were unavailable for 2 participants.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="4"/>
                    <measurement group_id="O2" value="48" spread="4"/>
                    <measurement group_id="O3" value="59" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.68</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Overall, treatment effect F value testing under the null hypothesis the equality of the average outcome over the three groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Spielberger State-Trait Anxiety Inventory Score [State]</title>
        <description>The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults.The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety). The scores are averaged over the trial.</description>
        <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Spielberger State-Trait Anxiety Inventory Score [State]</title>
          <description>The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults.The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety). The scores are averaged over the trial.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="1.16"/>
                    <measurement group_id="O2" value="33.8" spread="1.12"/>
                    <measurement group_id="O3" value="33.6" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.65</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Overall, treatment effect F value testing under the null hypothesis the equality of the average outcome over the three groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Penn Alcohol Craving Scale Score</title>
        <description>Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol. Scores are averaged over the trial.</description>
        <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Penn Alcohol Craving Scale Score</title>
          <description>Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol. Scores are averaged over the trial.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="0.91"/>
                    <measurement group_id="O2" value="10.8" spread="0.88"/>
                    <measurement group_id="O3" value="9.4" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.84</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Overall, treatment effect F value testing under the null hypothesis the equality of the average outcome over the three groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbohydrate-deficient Transferrin</title>
        <description>Lab test assessing history of heavy drinking with greater specificity than GGT. Higher levels are indicative of greater levels of drinking.</description>
        <time_frame>End of trial, generally 16 weeks</time_frame>
        <population>Post-randomization CDT was not collected for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Carbohydrate-deficient Transferrin</title>
          <description>Lab test assessing history of heavy drinking with greater specificity than GGT. Higher levels are indicative of greater levels of drinking.</description>
          <population>Post-randomization CDT was not collected for all participants.</population>
          <units>% CDT</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread=".26"/>
                    <measurement group_id="O2" value="2.19" spread=".26"/>
                    <measurement group_id="O3" value="1.96" spread=".28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.52</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimated parameter is the overall treatment main effect F statistic from the fitted ANCOVA model assessing the null hypothesis of equal values across the three groups</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Sedation on at Least One Occasion by a Participant</title>
        <description>Any reporting of feeling sedated/sleepy/drowsy</description>
        <time_frame>Every 1-2 weeks up to 16 weeks of active trial</time_frame>
        <population>Post-randomization data were unavailable for 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
          </group>
          <group group_id="O2">
            <title>30 Mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
          <group group_id="O3">
            <title>90 mg Baclofen</title>
            <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Sedation on at Least One Occasion by a Participant</title>
          <description>Any reporting of feeling sedated/sleepy/drowsy</description>
          <population>Post-randomization data were unavailable for 2 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>Threshold for significance is &lt;.05</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Table probability for Fisher's Exact</param_type>
            <param_value>.002</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout treatment and for 4 weeks after treatment ended.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Placebo: Pill containing no pharmacologically active substance.</description>
        </group>
        <group group_id="E2">
          <title>30 Mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen: Baclofen is a GABA-B agonist</description>
        </group>
        <group group_id="E3">
          <title>90 mg Baclofen</title>
          <description>Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen: Baclofen is a GABA-B agonist</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>Subject became very drowsy and fell asleep while driving though recovered and did not have an accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/low energy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Sleepiness, somnolence</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Feeling dizzy</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness/rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C Garbutt, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>984-974-2201</phone>
      <email>jc_garbutt@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

